The MRA with FDA - any Consequences for the QP?

On 2nd March 2017, the US FDA and the European Medicines Agency (EMA) informed that they concluded a so-called MRA (Mutual Recognition Agreement). Learn more about the FDA-EU MRA and the consequences for the Qualified Person (QP).


EMA's new Guideline on the Implementation of the ICH Q3D Guideline in the EU

Recently published, the EMA Guideline on the implementation of the requirements of the ICH Q3D Guideline provides support for API and medicinal product manufacturers. Learn more about what you have to consider with regard to the justification and documentation of elemental impurities in the dossier for a marketing authorisation.


EMA revises Guide on Pharmaceutical Water

According to the European Pharmacopoeia, it is allowed as of the 1st of April 2017 to produce water for injection (WFI) using cold i.e. non-distillation methods. Now, the European Medicines Agency EMA has published a concept paper on the revision of the "Note for Guidance on Quality of water for pharmaceutical use".


Recognition of Alternative Compendia (BP/EP/JP) by the FDA

In January 2017, FDA's Office of Pharmaceutical Quality revised the document "MAPP 5310.7" on the acceptability of standards from alternative compendia. This important FDA document is often unknown among the pharmaceutical industry. Learn more about the most important aspects of FDA's document "Acceptability of Standards from Alternative Compendia (BP/EP/JP)".


QP Declaration: Revised Questions and Answers

The Co-ordination group for Mutual Recognition and Decentralised Procedures - human (CMDh) of the Heads of Medicines Agencies has revised its Question and Answers Document on the QP Declaration.


New CMDh Q&A Document on the Implementation of the EU Falsified Medicines Directive

In March the CMDh published a new Q&A document to provide further guidance on the implementation of the EU Falsified Medicines Directive. Please find more information about the "CMDh clarifications on questions received on the implementation of the Falsified Medicines Directive".


Warning Letter for Japanese Sterile Manufacturer

Insufficient environmental monitoring as well as inexistent smoke studies on a RABS (Restricted Access Barrier System) resulted in a Warning Letter for the Japanese manufacturer Sato Pharmaceutical Co. Ltd.


API mixtures and CEP Procedure: What should be considered?

It is also possible to apply for a Certificate of Suitability for API mixtures. However, a few particularities have to be considered. Here, you can read about what must be observed when applying for a CEP for an API/auxiliary substances mixture or an API/antioxidant mixture.


Validation vs. Verification of Medical Devices - An Interesting FDA Warning Letter

It its cGMP regulations for medical devices (21 CFR 820 (Quality System Regulations), the FDA also addresses the topic of validation (21 CFR 820.75). In the course of its inspections, the authority reviews the validation of the manufacturing processes. The FDA criticised according deficiencies at a Taiwanese medical devices manufacturer with a Warning Letter.


MHRA Guideline on Re-Manufacturing of Single-Use Medical Devices

Last year the MHRA published a 11-page guidance about the re-manufacturing of single-use medical devices (SUDs). Alhough only valid for the UK the content of the MHRA Guidance on Single-Use Medical Devices is interesting.


EMA Concept Paper on Combination Products

Since February, 16th 2017 you can comment on a concept paper of the EMA on the development of a guideline with regard to the quality requirements of "combination products" - called "Drug-Device-Combination" (DCC) in the document.


USP drafts on viscoelastic properties of semisolids

The USP is requesting early input from stakeholders on two new proposed General Chapters regarding the characterization of viscoelastic properties of semisolids. Read more about the proposed chapters <915> Measurement of Structural Strength of Semisolds by Penetromety and <1912> Measurement of Hardness of Semisolids.



The European Medicines Agency (EMA) recently published Questions and Answers on good clinical practice (GCP) on its website. These Q&As include questions and corresponding answers regarding general considerations on how contracting should be addressed and contractual arrangements with vendors for electronic systems. Find out more about EMA´s "GCP matters" Q&As.


Annex 16 QP Certification: important Questions and Answers

What can a Supply Chain Diagram look like? How to rely on vendor-supplied samples? These are just two examples of the questions in conjunction with the "Certification by a Qualified Person and Batch Release" being now answered by an inspectorate.


Pro Generika - New Shareholder in the securPharm Manufacturer Database

On 15 March 2017, a common press release was published to announce the joining of Pro Generika e.V. as shareholder in the ACS PharmaProtect GmbH (ACS). ACS was founded in 2012 with the aim of developing and operating the manufacturer database in Germany. Read more about the joining of Pro Generika e.V. in the ACS PharmaProtect GmbH.


MHRA's Interpretation of Cross Contamination & PDEs

The British inspectorate MHRA has recently published a comprehensive document that goes into detail on the use of health based exposure limits and explains the cases where EMA's new concept must be applied. One essential element of that concept is EMA's Q&A Paper describing when a product should be classified as highly active. This Question & Answer Paper can be commented on until the end of April 2017. Read more here.


PIC/S statement to European Commission's ATMP GMP Guideline

The PIC/S published a harsh letter to the European Commission relating to their draft guideline on GMP for Advanced Therapy Medicinal Products (ATMP).


Ongoing developments in the field of ATMP

Beginning of February, the European Medicines Agency (EMA) published new information about Advanced Therapy Medicines and how to get to an increased ATMP development and patient access.


Feedback of the EQPA IMP Working Group on the Commission Delegated Regulation on GMP for IMPs

The IMP Working Group within the European QP Association sent in their comments to the EU Commission on the Commission Delegated Regulation on GMP for IMPs, incuding some recommendations.


Supplier Audits: Expectations clarified by Inspectorate

What the inspectorates expect regarding supply chain traceability and the role of the QP has been pointed out in a recent blog issued by the British MHRA.


GMP Newsletter

Sign up for the free of charge newsletters.

Sign up now!

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information